PMC4144710_01
PET-CT demonstrating the absorption in the left lung nodule and pleural thickening of the left base.
can-8-452fig1a.jpg
PMC4144710_01_can-8-452fig1a.jpg
figure1a
There was no evidence of metastases in other organs (Figure 1a). A new PET/CT was carried out, and it identified the permanence of the diffuse and nodular pleural thickening, predominantly at the base, but showing increased radiopharmaceutical uptake (SUV 17.7) (Figure 1b).
PMC4144710_02
PET-CT showing evidence of the presence of pleural thickening and increase of radiopharmaceutical capture.
can-8-452fig1b.jpg
PMC4144710_02_can-8-452fig1b.jpg
figure1b
Despite the findings that confirmed disease progression with the emergence of new pulmonary nodules, there was a moderate reduction of the diffuse pleural thickening on the left, but with increased FDG uptake (SUV 13.3) (Figure 2a). After six cycles of this treatment regimen, despite the partial response according to the response evaluation criteria in solid tumours (RECIST), the PET/CT showed persistent signs of pleurodesis in the base of the left hemithorax, keeping the radiopharmaceutical uptake as SUV 13.1 (Figure 2b).